SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Buys $33,800.00 in Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Jane Wasman acquired 20,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were bought at an average price of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director now owns 30,400 shares of the company's stock, valued at $51,376. This trade represents a 192.31% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

SELLAS Life Sciences Group Price Performance

SLS stock traded down $0.02 during midday trading on Friday, hitting $1.61. The company's stock had a trading volume of 2,418,475 shares, compared to its average volume of 1,566,215. The company's fifty day moving average price is $1.46 and its 200 day moving average price is $1.25. SELLAS Life Sciences Group, Inc. has a twelve month low of $0.77 and a twelve month high of $2.12. The stock has a market capitalization of $160.64 million, a P/E ratio of -2.33 and a beta of 2.25.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. Equities analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Institutional investors have recently modified their holdings of the business. Opus Capital Group LLC raised its position in shares of SELLAS Life Sciences Group by 5.5% in the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after buying an additional 12,400 shares in the last quarter. Brooklyn FI LLC acquired a new stake in SELLAS Life Sciences Group during the fourth quarter worth about $677,000. Geode Capital Management LLC increased its holdings in SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after buying an additional 128,355 shares during the period. Northern Trust Corp boosted its position in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after acquiring an additional 33,878 shares in the last quarter. Finally, Anson Funds Management LP increased its stake in SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock valued at $1,240,000 after acquiring an additional 398,431 shares during the last quarter. Institutional investors own 17.38% of the company's stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.